SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple shares experienced significant volatility surrounding the company's product launch event, where the debut of the 'iPhone Duo' foldable device and updates to the Apple Watch and AirPods drew a polarized reaction from traders. While some investors viewed the new hardware and AI-integrated features as catalysts for growth, others engaged in 'sell-the-news' trading, leading to intense debate over the product's premium pricing and lack of perceived innovation.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is trending following a significant rebound driven by the announcement of a massive share buyback and cancellation program, alongside a tentative wage deal with its union. Investors are highlighting the company's dominant market position in high-bandwidth memory (HBM) for AI applications and its commitment to increasing shareholder returns.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a record quarterly operating income and news of a director purchasing 55,000 shares, which has sparked debate between bulls highlighting the company's strong cash position and collectibles growth versus bears focusing on declining revenue and ongoing concerns about potential stock dilution.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending as traders focus on the company's defense-related contracts and long-term positioning in the drone industry, with some investors viewing current price levels as a strong buying opportunity ahead of upcoming earnings. While bullish sentiment is supported by a robust backlog and contract wins, others remain skeptical or cautious, citing high volatility and skepticism toward recent price action.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is experiencing a rebound as traders react to positive developments in quantum computing and enterprise AI partnerships, with many market participants viewing the stock as undervalued following its recent sell-off. The community is split, with some traders optimistic about a continued recovery toward former highs while others maintain bearish skepticism regarding leadership and long-term performance.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is experiencing increased selling pressure as traders debate whether the stock is undergoing a healthy reset or a broader cooling of the AI infrastructure trade. While long-term bulls remain focused on the company's critical role in data center power and thermal management, some investors are citing valuation concerns and sector-wide volatility as reasons for the pullback.

Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Durham, NC.

Opus Genetics Inc.

Opus Genetics (IRD) is trending following positive Phase 1/2 clinical trial results for its OPGx-BEST1 gene therapy, which showed visual function and retinal sensitivity improvements in patients. While investors are highly bullish on the company's progress and upcoming catalysts, some traders express caution regarding potential dilution risks given the company's cash runway.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following positive but mixed Phase 3 results for sonelokimab in psoriatic arthritis, which met primary endpoints but showed efficacy comparable to existing therapies rather than clear superiority. The community is divided between long-term bullish investors focused on the potential for stronger results at the 52-week mark and HS BLA submission, and bears concerned about management's dilution strategy and the lack of a clear acquisition catalyst.

ServiceTitan, Inc. engages in the collection of field service activities required to install, maintain, and service the infrastructure and systems of residences and commercial buildings. The company was founded by Ara Mahdessian and Vahe Kuzoyan on June 8, 2008 and is headquartered in Glendale, CA.

ServiceTitan Inc. - Ordinary Shares - Class A

ServiceTitan 

ServiceTitan shares are experiencing significant volatility and a steep decline following its recent quarterly earnings report, where the company's third-quarter revenue guidance slightly missed analyst expectations. While some traders view the sell-off as an overreaction given the company's long-term growth potential in the trades industry, others express concerns about the deceleration in growth and a management change.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech shares are experiencing extreme volatility and a significant price decline following disappointing Q1 revenue guidance and management's comments regarding persistent customer acquisition cost challenges tied to advertising algorithm disruptions. The community is sharply divided, with bulls viewing the sell-off as an irrational overreaction given the company's strong cash position and active share buyback program, while bears remain skeptical of management's transparency and the long-term impact of the advertising headwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The price move appears driven by optimistic trader sentiment regarding the company's potential as an acquisition target in the weight loss and metabolic disease sector. This speculation is being fueled by broader industry M&A activity and recent pharmaceutical trial failures from competitors, leading investors to focus on the company's clinical pipeline as a strategic asset.

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus

KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.



BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.

KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema

Kodiak launches a global phase III study of KSI-501 in DME, testing its dual IL-6 and VEGF approach for durable disease control.

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.

Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates

PRGO tops Q2 EPS estimates as Infant Formula sales jump, helping offset softer demand and divestiture impacts while the company reaffirms 2026 guidance.

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus 

Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.

Reported GAAP EPS of -$0.12 up 55.56% YoY

Altimmune incurred an increased net loss and higher research and development expenses during the quarter while facing ongoing operational and regulatory risks associated with the development of its product candidates.

Altimmune achieved significant clinical milestones, including the initiation of a Phase 3 MASH trial and positive Phase 2 results in AUD, while advancing enrollment for its ALD development program.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

 VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t 

Equity

Bullish Sentiment

Yes, day one

Yes, but I'll wait for reviews

No, too expensive

No, not interested in a foldable

Apple unveiled its first foldable iPhone, reportedly called the iPhone Duo, at its September 9 event, with pricing starting at $2,000 for the 256GB model. Will you buy the $2,000 iPhone Duo? Vote and explain your reasoning in the comments.

Apple ($AAPL) just unveiled its first foldable iPhone, the iPhone Duo, starting at $2,000. Will you buy it?

Stocktwits

) just unveiled its first foldable iPhone, the iPhone Duo, starting at $2,000. Will you buy it?

Feed

News

Sentiment

Earnings

Fundamentals

Info

ALT Altimmune Inc

Fundamentals

Latest ALT News